At the end of 2018, iVascular SLU, a European medical device company, made an investment in NaviGate Cardiac Structures, Inc. and will be instrumental in helping the company’s developments by providing its expertise in fabrication and manufacturing of various components of our atrioventricular valved stent bioprosthesis system. This will be a very fruitful association that will accelerate our entry into the realm of structural heart disease.
- Early Feasibility Study (EFS) for NCSI’s GATE™ System is approved by FDA
- iVascular SLU, Barcelona Invests in NaviGate Cardiac Structures, Inc.
- Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada.
- NaviGate Cardiac Structures, Inc., presents data of studies on the Gate™ valved stent for correction of Functional Tricuspid Regurgitation at Paris PCR2016.